Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Oragenics starts AG013 dosing in Phase II trial to treat oral mucositis

Go Top